Bright Path Laboratories to Collaborate in NSF Engines Development Program

Article

The NSF-sponsored program aims to help partners collaborate to create opportunities for significant economic, societal, and technological opportunities for growth in their regions.

The National Science Foundation (NSF) awarded The Puerto Rico Science, Technology & Research Trust (Trust) $1 million as part of NSF’s Regional Innovation Engines program. The Trust is one of 44 unique teams to receive the first-ever NSF Engines Development Awards, which aims to help partners collaborate on economic, societal, and technological opportunities for significant growth in their regions. Bright Path Laboratories, a US-based advanced drug development and manufacturing company, will participate as a collaborator in this award.

According to a company press release, the “Advancing Biopharmaceutical Technologies and Manufacturing Practices (P.R.)” award aims to lay the groundwork for establishing a NSF Regional Innovation Engine in Puerto Rico. This includes developing its structure and scope, as well as establishing partnerships to advance biopharmaceutical technologies and manufacturing practices. If sufficient progress is made after two years, the Trust will be eligible for an NSF Engines Award of up to $160 million for up to 10 years.

“The necessity to invest in innovative pharmaceutical manufacturing in the United States has never been greater. Bright Path’s … continuous flow advanced manufacturing platform is an integral part of our nation’s supply chain readiness initiative,” said Tony Quinones, co-founder and CEO, Bright Path Laboratories, in the release. “We are very pleased that NSF has chosen the Trust as an awardee and excited to expand and solve the immediate and long-term challenges in our medicinal supply chain through our transformative technology.”

Source: Bright Path Laboratories

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content